Martin Olovsson

We are all passionate about improving cancer patients´ lives with patient-centric digital solutions. At ScientificMed, we provide healthcare givers and patients access to state-of-the-art Digital Therapeutics with the goal of improving treatment outcomes, empowering the patients, and increasing the efficiency of healthcare delivery.

Aqilion is a Swedish life science company. We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care. Aqilion harbors the backbone core management, financing resources and business administration together with a network of skilled competences and seek to match that with external sources of innovation from academia or industry. Aqilion pursues and transforms ideas aimed at testing and refining science into clinical translation. The goal is to deliver clinical proof-of-concept and an interesting value proposition to attract industrial partners fitted to drive the late phases of clinical development and commercialization.

LIF is the trade association for the research-based pharmaceutical industry in Sweden. LIF has about 90 member companies who represent approximately 80 percent of the total sales of pharmaceuticals in Sweden. LIF represents its members in issues of common concern. LIF is also a service organisation for the member companies, informing them on questions vital to the industry.

We are all passionate about improving cancer patients´ lives with patient-centric digital solutions. At ScientificMed, we provide healthcare givers and patients access to state-of-the-art Digital Therapeutics with the goal of improving treatment outcomes, empowering the patients, and increasing the efficiency of healthcare delivery.

Aqilion is a Swedish life science company. We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care. Aqilion harbors the backbone core management, financing resources and business administration together with a network of skilled competences and seek to match that with external sources of innovation from academia or industry. Aqilion pursues and transforms ideas aimed at testing and refining science into clinical translation. The goal is to deliver clinical proof-of-concept and an interesting value proposition to attract industrial partners fitted to drive the late phases of clinical development and commercialization.

WntResearch is developing a completely new type of cancer drug that inhibits the ability of tumour cells to spread in the body and form metastases. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobility and spread of cancer cells thus preventing metastases from occurring. Although current cancer treatment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 per cent of all cancerrelated deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer. WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com.

OnDosis Dosage Manager delivers flexible and individualized dosing of oral medicines formulated as pellets, granules, mini tablets or powders. We are writing a new chapter in personalized medicine, and enable closed loop disease management. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes. OnDosis was founded as a spin-out from AstraZeneca in 2017 and is headquartered in Gothenburg, Sweden.

LIF is the trade association for the research-based pharmaceutical industry in Sweden. LIF has about 90 member companies who represent approximately 80 percent of the total sales of pharmaceuticals in Sweden. LIF represents its members in issues of common concern. LIF is also a service organisation for the member companies, informing them on questions vital to the industry.